FLT3 and acute myeloid leukemia: Of note, in a recent report of a large randomized trial, Stone and colleagues [21] showed a significant survival benefit with the addition of the multi-target kinase inhibitor midostaurin to standard chemotherapy for AML patients bearing FLT3-ITD or TKD aberrations, an important finding that hopefully will pave its way into daily clinical practice.